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↑What is “already known” in this topic: 
ARVC/D frequency affects 1 in 1000 individuals, with a mean 
diagnosed age of 31 years. Heterozygous mutation in PKP2 
gene, encoding Plakophilin-2, is the common cause of 
ARVC/D.   
→What this article adds: 
A novel mutation is reported as well as segregation analysis of 
this mutation within the family. In silico analysis of the novel 
mutation, it was shown that its pathogenicity leads to ARVC 
phenotype. The role of modifier genes is indicated using in-
teractome analysis. Intrafamilial phenotypic variability, which 
is an important issue in genetic counseling in ARVC/D, is pre-
sented in an Iranian family.  
 
A novel PKP2 mutation and intrafamilial phenotypic 
variability in ARVC/D  
Nejat Mahdieh 1,2, Sedigheh Saedi1,2, Mahdieh Soveizi1, Bahareh Rabbani1,2,3, Nasim Najafi2,  
Majid Maleki*1,2  
 Received: 31 Sep 2017                 Published: 6 Feb 2018 
Abstract 
    Background: Arrhythmogenic ventricular cardiomyopathy (AVC) is an inherited cardiac disorder affecting 1 in 1000 individuals 
worldwide. The mean diagnosed age of disease is 31 years. In this article, an Iranian family reported that they were affected by ARVC 
due to a novel PKP2 mutation.  
   Methods: Clinical evaluations, 12-lead ECG, CMR, and signal-averaged ECG were performed. After DNA extraction, genetic test-
ing was done, and PCR-sequencing was applied to find causal mutations. Segregation analysis was also performed for the family. 
   Results: ARVC criteria were documented in the patients. Genetic testing revealed a novel chain termination mutation (p.Tyr168Ter) 
in PKP2 gene; this mutation was transmitted from the mother to her 23-year-old son, but only the son was affected with ARVC.  
   Conclusion: Modifier genes were indicated using interactome analysis of Plakophilin 2 protein (PKP2); they might have led to phe-
notypic variability through cellular mechanisms, such as nonsense-mediated mRNA decay. At least, 9 proteins were identified that 
might have affected Plakophilin 2 protein function, and consequently, rationalizing this intrafamilial phenotypic variability. This study 
highlighted the role of modifier genes involved in ARVC as well as the major role of PKP2 mutation in developing the disease in our 
population. 
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Introduction 
Arrhythmogenic ventricular cardiomyopathy (AVC or 
previously ARVC/D, arrhythmogenic right ventricular 
cardiomyopathy/dysplasia) is an inherited cardiac disease 
defined by abnormal structure and function of the right 
and possibly the left ventricle, resulting in the progressive 
fibrofatty replacement of myocardium (1). It has been 
estimated that ARVC/D frequency affects 1 in 1000 indi-
viduals, with a mean diagnosed age of 31 years (2). Clini-
cal symptoms of the affected individuals include palpita-
tions, syncope, sudden death, atypical chest pain, and 
dyspnea ventricular heart failure. Based on the 2010 task 
force criteria (3), ARVC/D is diagnosed by major and 
minor diagnostic criteria of echocardiographic, arrhyth-
mic, and tissue abnormalities. Approximately 30% to 50% 
of the patients show a positive family history (4). Muta-
tions in desmosome coding genes have been reported to 
cause ARVC in 40% to 50% of the cases (5). Desmo-
somes act as anchors between myocytes and intermediate 
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filaments/cells and involve in Wnt/B-Catenin signaling. 
Plakophilin-2 protein, which participates in intercellular 
coupling and interacts with voltage-gated sodium channel 
complex, has an essential role in heart morphogenesis (6). 
Heterozygous mutation in PKP2 gene, encoding 
Plakophilin-2, is the common cause of ARVC/D (7-9). 
More than 200 mutations in PKP2 gene have been report-
ed so far, which are dominantly categorized as point muta-
tions. Here, a chain termination variant in PKP2 gene is 
described for the first time that causes ARVC/D with low 
penetrance. 
 
Methods 
Clinical evaluations, ECG, 12-lead ECG, CMR, and 
SAECG were performed. Family history was also record-
ed. After obtaining the signed informed consent form, 5 
mL peripheral blood was used for DNA extraction using 
standard methods. To date, mutations of  7 major genes 
including RYR2, TMEM43, DSP, PKP2, DSG2, DSC2, 
and JUP have been reported to cause ARVC/D. Genetic 
testing was performed. Briefly, coding regions of PKP2 
gene (NM_001005242) (exons and intron boundaries) 
were amplified using PCR reactions (primers are available 
upon request), and direct sequencing was performed using 
BigDye protocol by sequencing analyzer ABI 3500 (PE 
Applied BioSystems, US). 
 
Results 
A 23-year-old male presented with an earlier history of 
syncope was referred to the hospital. Electrocardiogram 
(ECG) records showed a broad QRS tachycardia with left 
bundle branch block (LBBB) morphology and superior 
axis, with a rate of 260 beats/minute terminated by DC-
shock (Fig. 1a). Medical history showed repeated episodes 
of sudden onset palpitation without syncope. A history of 
sudden cardiac arrest in the patient’s aunt was recorded. 
The resting 12-lead ECG was consistent with T-wave 
inversion in leads V1-V5, with no bundle branch block 
patterns (Fig. 1b). Laboratory tests were within the normal 
ranges, from mild to moderate LV systolic dysfunction, 
with an estimated ejection fraction of 40% to 45%. The 
right ventricle (RV) was also severely enlarged, with 
moderate to severe dysfunction. Cardiac magnetic reso-
nance imaging (CMR) of the patient revealed diffuse evi-
dence of localized dyskinesia and microaneurismal for-
mation in the anterior RV free wall, inferior RV wall, and 
the right ventricular outflow tract (RVOT) region in addi-
tion to localized LV myocardial thinning, and a few mi-
a b  
Fig. 1. (a) 12-Lead ECG of the patient showing VT with LBBB morphology and superior axis. (b) Resting 12-Lead ECG after admission 
to our hospital illustrating sinus rhythm and T-wave inversion in V1-V5. 
 
a b c  
Fig. 2. CMR images depicting RV dilation and aneurysm formation (a) and diffuse fibrosis in RV and parts of LV (b and c) (videos are 
available upon request). 
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croaneurismal formation, especially in mid and apico-
lateral LV segments. Diffuse subepicardial to transmural 
fibrosis of RV inferior and anterior wall extended close to 
RVOT, and RV apex was determined in late gadolinium 
enhancement (LGE) images; moreover, LV inferoapical 
segment and a subepicardial fibrosis of mid lateral LV 
segment were found (Fig. 2). 
Signal-averaged ECG (SAECG) indicated the presence 
of late potentials. Taken together, the definite clinical di-
agnosis was made according to 2010 Task Force major 
and minor criteria for diagnosis of ARVC/D (3).  
Sequencing of the PKP2 gene showed a new heterozy-
gous stop codon mutation in Exon 3, c.504C>G 
(TAC>TAG), and p.Tyr168Ter (Fig. 3). This variant has 
not yet been reported in the literature. However, since the 
mutation leads to formation of a stop codon terminating 
the translation, the resulting truncated protein 
(p.Tyr168Ter) causes pathogenic effect.  
Cascade screening of first-degree family members of 
this individual for the new variant showed that his mother 
is heterozygote, but the mutation was not found in his 
brother and his father. His mother underwent a compre-
hensive cardiological work-up and ARVC was not diag-
nosed in this individual.  
Protein–protein interaction analysis was performed us-
ing STRING10 to find whether the proteins interact 
with Plakophilin 2. 
 
Discussion 
A 23-year-old male (III2) was presented with diagnosed 
ARVC due to a novel chain termination mutation in the 
PKP2 gene. ARVC was diagnosed according to the 2010 
Task Force criteria. Genetic testing was performed for his 
family, which showed mutation in his mother (II2), fol-
lowing an autosomal-dominant inheritance. 
Genetic testing can be used for possible ARVC patients 
(1 major or 2 minor criteria of the Heart Rhythm Socie-
ty/European Heart Rhythm Association’s Expert Consen-
sus Statement). Mutation identification would be useful 
for screening other family members, so that effective life 
style and predictive management could be used. 
PKP2 mutations are the most common cause of ARVC 
in some populations; mutation frequency has been report-
ed to range from 10% to 78% in ARVC patients (9, 10). 
To date, nearly 200 mutations have been described to be 
pathogenic in PKP2 gene (http://www.hgmd.cf.ac.uk/). 
c.504C>G (p.Tyr168Ter) in PKP2 gene, which is a non-
sense mutation creating a stop codon at 168 position of the 
protein. Of 68 reported substitution mutations, 24 are non-
sense (http://www.hgmd.cf.ac.uk/). In general, nonsense 
mutations are responsible for nearly11% of all mutations 
leading to inherited disease and approximately 20% of 
disease-associated point mutations within coding regions 
(11). 
As mentioned, p.Tyr168Ter in PKP2 was observed in 
both the son and his mother, but the mother’s condition 
was apparently normal. The patient underwent successful 
ICD implantation for secondary prophylaxis of sudden 
cardiac death and was discharged from the hospital in a 
good condition after 2 days. To find out why his mother 
had no diseased phenotype, we considered several hy-
potheses; however, she might have shown very small de-
grees of the phenotype, so she was underdiagnosed. On 
the other hand, this mutation may have a reduced pene-
trance. There are different factors affecting the penetrance 
of a mutation, such as lifestyle, genetic variations, sport 
 
Fig. 3. (a) Pedigree of the family. Individual III2 and II2 had heterozygous c.504C>G. (b) Electropherograms of the patient showed a heterozygous 
stop codon mutation in Exon 3, c.504C>G, TAC>TAG, and p.Tyr168Ter.   
 
 
Fig. 4. Protein–protein interaction network of Plakophilin 2 with 
STRING10. Plakophilin 2 is one of several proteins that make up 
desmosomes that provide strength to the myocardium and are in-
volved in signaling between neighboring cells. Predicted functional 
partners are as follow: DSP: desmoplakin; DSG2: desmoglein 2; 
DSC2: desmocollin 2; DSG1: desmoglein 1; DSC1: desmocollin 1; 
POLR3A: polymerase (RNA) III, (DNA directed) polypeptide A; 
GJA1: gap junction protein, alpha 1; MARK3A: MAP/microtubule 
affinity-regulating kinase 3; SCN5A: sodium channel, voltage-
gated, type V, alpha subunit. 
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activity, and gender (12-16). However, interaction analy-
sis of PKP2 protein by STRING database Version 10.0 
(17) was performed to check the probable modifier genes. 
STRING is a database of known and predicted proteins 
and showed that PKP2 gene is related to desmoplakin 
[DSP], Desmoglein 2 [DSG2], Desmocollin 2 [DSC2], 
Desmoglein 1 [DSG1], gap junction protein, Alpha 1 
(GJA1), polymerase (RNA) III [POLR3A], 
MAP/microtubule affinity-regulating kinase 3 
[MARK3A], sodium channel, voltage-gated, type V, alpha 
subunit (SCN5A), and Desmocollin 1 (DSC1) (Fig. 4). 
DSP is a major high molecular weight protein of desmo-
somes that plays a role in assembling the desmosomal 
cadherin- plakoglobin complexes to discrete transmem-
brane domains and anchor desmosomal intermediate fila-
ments. DSG2, DSC2, DSG1, and DSC1 are components 
of intercellular desmosome junctions. DSG1 and DSC1 
may also contribute to epidermal cell positioning by me-
diating differential adhesiveness between cells that ex-
press different isoforms. Therefore, variants of these genes 
leading to different isoforms of a protein may influence 
and affect the penetrance and expression of this mutation. 
Hence, other related factors, eg, various isoforms of the 
protein involved in desmosome junctions, could influence 
or compensate for Plakophilin 2 deficiency caused by this 
nonsense variant; in other words, although Plakophilin 2 
had a defective function in the mother, other related pro-
teins could compensate this deficiency (of Plakophilin 2, 
having Tyr168Ter mutation), while no such phenomenon 
was found in her son. However, this hypothesis should be 
investigated in this family.  Finding this gene is an inter-
esting idea because it may have a significant impact on 
unravelling the involved factors in NMD process in this 
individual and can open a new window to the treatment of 
the disease. Further studies are needed to find the preva-
lence of PKP2 mutations and modifier genes. 
Alternatively, phenotypic variability may be due to ef-
fects of modifying factors including environmental and 
genetic agents interacting with deficient Plakophilin 2. 
Modifier factors may usually influence the expression, age 
at onset, and progression of the disease. It is likely that the 
existence of an unknown modifier effect, such as delE120 
mutation in GJB2 gene, may modulate this scenario (14). 
Nonsense mutations result in a premature termination co-
don and most often lead to complete loss of protein and 
reduce mRNA levels because of the nonsense-mediated 
mRNA decay (NMD). NMD, as an mRNA quality-control 
mechanism, starts selective degradation of mutant tran-
scripts and improves cellular surveillance (18). In the 
studied family, NMD may decrease the severity of disease 
in his mother. 
 
Conclusion 
This study, as a first report of PKP2 mutation in an Ira-
nian family, highlights the role of modifier genes involved 
in ARVC. Finding the cause of phenotypic variability due 
to this variant within the family may shed light on the road 
of treatment approach for ARVC. Also, PKP2 mutation 
may play a major role in the development of disease in our 
population. 
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